Which has better earnings & valuation, TNYA or PDSB?

Tenaya Therapeutics is trading at a lower price-to-earnings ratio than PDS Biotechnology, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Tenaya Therapeutics N/A N/A -$90.60M -$0.53 N/A PDS Biotechnology N/A N/A -$34.50M -$0.67 N/A

Is TNYA or PDSB more profitable?

Tenaya Therapeutics' return on equity of -83.75% beat PDS Biotechnology's return on equity. Company Net Margins Return on Equity Return on Assets Tenaya Therapeutics N/A -83.75% -66.53% PDS Biotechnology N/A -346.02% -102.36%

Does the media refer more to TNYA or PDSB?

In the previous week, Tenaya Therapeutics had 16 more articles in the media than PDS Biotechnology. MarketBeat recorded 17 mentions for Tenaya Therapeutics and 1 mentions for PDS Biotechnology. Tenaya Therapeutics' average media sentiment score of 0.46 beat PDS Biotechnology's score of 0.00 indicating that Tenaya Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tenaya Therapeutics 3 Very Positive mention(s) 2 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral PDS Biotechnology 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is MOLN or PDSB more profitable?

Molecular Partners' return on equity of -66.62% beat PDS Biotechnology's return on equity. Company Net Margins Return on Equity Return on Assets Molecular Partners N/A -66.62% -54.85% PDS Biotechnology N/A -346.02% -102.36%

Does the media refer more to MOLN or PDSB?

In the previous week, Molecular Partners and Molecular Partners both had 1 articles in the media. Molecular Partners' average media sentiment score of 0.75 beat PDS Biotechnology's score of 0.00 indicating that Molecular Partners is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Molecular Partners 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive PDS Biotechnology 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to PDSB or IMDX?

In the previous week, Oncocyte had 2 more articles in the media than PDS Biotechnology. MarketBeat recorded 3 mentions for Oncocyte and 1 mentions for PDS Biotechnology. PDS Biotechnology's average media sentiment score of 0.00 equaled Oncocyte'saverage media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment PDS Biotechnology 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Oncocyte 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer YDES or PDSB?

PDS Biotechnology has a consensus target price of $9.00, indicating a potential upside of 1,131.02%. Given PDS Biotechnology's stronger consensus rating and higher probable upside, analysts clearly believe PDS Biotechnology is more favorable than YD Bio. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score YD Bio 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 PDS Biotechnology 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33

Which has stronger earnings & valuation, YDES or PDSB?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio YD Bio N/A N/A N/A N/A N/A PDS Biotechnology N/A N/A -$34.50M -$0.67 N/A

Is YDES or PDSB more profitable?

YD Bio's return on equity of 0.00% beat PDS Biotechnology's return on equity. Company Net Margins Return on Equity Return on Assets YD Bio N/A N/A N/A PDS Biotechnology N/A -346.02% -102.36%

Does the media favor YDES or PDSB?

In the previous week, YD Bio and YD Bio both had 1 articles in the media. YD Bio's average media sentiment score of 0.00 equaled PDS Biotechnology'saverage media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment YD Bio 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral PDS Biotechnology 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better valuation & earnings, PDSB or ABOS?

Acumen Pharmaceuticals is trading at a lower price-to-earnings ratio than PDS Biotechnology, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio PDS Biotechnology N/A N/A -$34.50M -$0.67 N/A Acumen Pharmaceuticals N/A N/A -$121.33M -$1.86 N/A

Is PDSB or ABOS more profitable?

Acumen Pharmaceuticals' return on equity of -123.07% beat PDS Biotechnology's return on equity. Company Net Margins Return on Equity Return on Assets PDS Biotechnology N/A -346.02% -102.36% Acumen Pharmaceuticals N/A -123.07% -79.41%

Does the media refer more to PDSB or ABOS?

In the previous week, Acumen Pharmaceuticals had 2 more articles in the media than PDS Biotechnology. MarketBeat recorded 3 mentions for Acumen Pharmaceuticals and 1 mentions for PDS Biotechnology. PDS Biotechnology's average media sentiment score of 0.00 equaled Acumen Pharmaceuticals'average media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment PDS Biotechnology 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Acumen Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

PDS Biotechnology (PDSB) Competitors

$0.73 -0.04 (-5.70%)

As of 04:00 PM Eastern

Compare

PDSB vs. TNYA, MOLN, IMDX, YDES, and ABOS

Should you buy PDS Biotechnology stock or one of its competitors? PDS Biotechnology's main competitors and comparable companies include Tenaya Therapeutics (TNYA), Molecular Partners (MOLN), Oncocyte (IMDX), YD Bio (YDES), and Acumen Pharmaceuticals (ABOS). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does PDS Biotechnology compare to Tenaya Therapeutics?

Tenaya Therapeutics (NASDAQ:TNYA) and PDS Biotechnology (NASDAQ:PDSB) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, earnings, dividends, media sentiment, valuation, profitability and institutional ownership.

Tenaya Therapeutics is trading at a lower price-to-earnings ratio than PDS Biotechnology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tenaya Therapeutics	N/A	N/A	-$90.60M	-$0.53	N/A
PDS Biotechnology	N/A	N/A	-$34.50M	-$0.67	N/A

In the previous week, Tenaya Therapeutics had 16 more articles in the media than PDS Biotechnology. MarketBeat recorded 17 mentions for Tenaya Therapeutics and 1 mentions for PDS Biotechnology. Tenaya Therapeutics' average media sentiment score of 0.46 beat PDS Biotechnology's score of 0.00 indicating that Tenaya Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tenaya Therapeutics	3 Very Positive mention(s)	2 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
PDS Biotechnology	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

90.5% of Tenaya Therapeutics shares are held by institutional investors. Comparatively, 26.8% of PDS Biotechnology shares are held by institutional investors. 2.5% of Tenaya Therapeutics shares are held by insiders. Comparatively, 8.4% of PDS Biotechnology shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Tenaya Therapeutics has a beta of 2.83, suggesting that its stock price is 183% more volatile than the broader market. Comparatively, PDS Biotechnology has a beta of 1.62, suggesting that its stock price is 62% more volatile than the broader market.

Tenaya Therapeutics' return on equity of -83.75% beat PDS Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tenaya Therapeutics	N/A	-83.75%	-66.53%
PDS Biotechnology	N/A	-346.02%	-102.36%

Tenaya Therapeutics currently has a consensus target price of $4.00, suggesting a potential upside of 442.45%. PDS Biotechnology has a consensus target price of $9.00, suggesting a potential upside of 1,131.02%. Given PDS Biotechnology's higher possible upside, analysts plainly believe PDS Biotechnology is more favorable than Tenaya Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tenaya Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86
PDS Biotechnology	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Summary

Tenaya Therapeutics beats PDS Biotechnology on 10 of the 13 factors compared between the two stocks.

How does PDS Biotechnology compare to Molecular Partners?

Molecular Partners (NASDAQ:MOLN) and PDS Biotechnology (NASDAQ:PDSB) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, media sentiment, dividends, earnings, profitability, risk and institutional ownership.

Molecular Partners presently has a consensus price target of $8.38, suggesting a potential upside of 103.28%. PDS Biotechnology has a consensus price target of $9.00, suggesting a potential upside of 1,131.02%. Given PDS Biotechnology's stronger consensus rating and higher probable upside, analysts clearly believe PDS Biotechnology is more favorable than Molecular Partners.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Molecular Partners	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
PDS Biotechnology	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Molecular Partners has a beta of 1.08, suggesting that its stock price is 8% more volatile than the broader market. Comparatively, PDS Biotechnology has a beta of 1.62, suggesting that its stock price is 62% more volatile than the broader market.

Molecular Partners' return on equity of -66.62% beat PDS Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Molecular Partners	N/A	-66.62%	-54.85%
PDS Biotechnology	N/A	-346.02%	-102.36%

26.6% of Molecular Partners shares are held by institutional investors. Comparatively, 26.8% of PDS Biotechnology shares are held by institutional investors. 5.9% of Molecular Partners shares are held by company insiders. Comparatively, 8.4% of PDS Biotechnology shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

PDS Biotechnology has lower revenue, but higher earnings than Molecular Partners. Molecular Partners is trading at a lower price-to-earnings ratio than PDS Biotechnology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Molecular Partners	$5.65M	29.45	-$74.41M	-$1.94	N/A
PDS Biotechnology	N/A	N/A	-$34.50M	-$0.67	N/A

In the previous week, Molecular Partners and Molecular Partners both had 1 articles in the media. Molecular Partners' average media sentiment score of 0.75 beat PDS Biotechnology's score of 0.00 indicating that Molecular Partners is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Molecular Partners	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
PDS Biotechnology	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

PDS Biotechnology beats Molecular Partners on 7 of the 11 factors compared between the two stocks.

How does PDS Biotechnology compare to Oncocyte?

PDS Biotechnology (NASDAQ:PDSB) and Oncocyte (NASDAQ:IMDX) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, earnings, media sentiment, profitability, dividends, risk and institutional ownership.

PDS Biotechnology currently has a consensus target price of $9.00, suggesting a potential upside of 1,131.02%. Oncocyte has a consensus target price of $12.00, suggesting a potential upside of 151.57%. Given PDS Biotechnology's stronger consensus rating and higher probable upside, equities research analysts clearly believe PDS Biotechnology is more favorable than Oncocyte.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PDS Biotechnology	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Oncocyte	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

PDS Biotechnology has a beta of 1.62, suggesting that its share price is 62% more volatile than the broader market. Comparatively, Oncocyte has a beta of 1.79, suggesting that its share price is 79% more volatile than the broader market.

PDS Biotechnology has a net margin of 0.00% compared to Oncocyte's net margin of -2,454.64%. Oncocyte's return on equity of 0.00% beat PDS Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PDS Biotechnology	N/A	-346.02%	-102.36%
Oncocyte	-2,454.64%	N/A	-96.96%

26.8% of PDS Biotechnology shares are held by institutional investors. Comparatively, 55.4% of Oncocyte shares are held by institutional investors. 8.4% of PDS Biotechnology shares are held by insiders. Comparatively, 2.2% of Oncocyte shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

PDS Biotechnology has higher earnings, but lower revenue than Oncocyte. Oncocyte is trading at a lower price-to-earnings ratio than PDS Biotechnology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PDS Biotechnology	N/A	N/A	-$34.50M	-$0.67	N/A
Oncocyte	$4.05M	38.03	-$50.22M	-$1.48	N/A

In the previous week, Oncocyte had 2 more articles in the media than PDS Biotechnology. MarketBeat recorded 3 mentions for Oncocyte and 1 mentions for PDS Biotechnology. PDS Biotechnology's average media sentiment score of 0.00 equaled Oncocyte'saverage media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
PDS Biotechnology	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Oncocyte	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

PDS Biotechnology beats Oncocyte on 7 of the 13 factors compared between the two stocks.

How does PDS Biotechnology compare to YD Bio?

YD Bio (NASDAQ:YDES) and PDS Biotechnology (NASDAQ:PDSB) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their risk, valuation, analyst recommendations, institutional ownership, profitability, media sentiment, dividends and earnings.

In the previous week, YD Bio and YD Bio both had 1 articles in the media. YD Bio's average media sentiment score of 0.00 equaled PDS Biotechnology'saverage media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
YD Bio	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
PDS Biotechnology	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

YD Bio's return on equity of 0.00% beat PDS Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
YD Bio	N/A	N/A	N/A
PDS Biotechnology	N/A	-346.02%	-102.36%

PDS Biotechnology has a consensus target price of $9.00, indicating a potential upside of 1,131.02%. Given PDS Biotechnology's stronger consensus rating and higher probable upside, analysts clearly believe PDS Biotechnology is more favorable than YD Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
YD Bio	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
PDS Biotechnology	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

26.8% of PDS Biotechnology shares are owned by institutional investors. 8.4% of PDS Biotechnology shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
YD Bio	N/A	N/A	N/A	N/A	N/A
PDS Biotechnology	N/A	N/A	-$34.50M	-$0.67	N/A

Summary

PDS Biotechnology beats YD Bio on 5 of the 7 factors compared between the two stocks.

How does PDS Biotechnology compare to Acumen Pharmaceuticals?

PDS Biotechnology (NASDAQ:PDSB) and Acumen Pharmaceuticals (NASDAQ:ABOS) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, dividends, risk, analyst recommendations, profitability, institutional ownership, valuation and earnings.

PDS Biotechnology presently has a consensus price target of $9.00, indicating a potential upside of 1,131.02%. Acumen Pharmaceuticals has a consensus price target of $8.00, indicating a potential upside of 229.22%. Given PDS Biotechnology's higher possible upside, research analysts plainly believe PDS Biotechnology is more favorable than Acumen Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PDS Biotechnology	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Acumen Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

In the previous week, Acumen Pharmaceuticals had 2 more articles in the media than PDS Biotechnology. MarketBeat recorded 3 mentions for Acumen Pharmaceuticals and 1 mentions for PDS Biotechnology. PDS Biotechnology's average media sentiment score of 0.00 equaled Acumen Pharmaceuticals'average media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
PDS Biotechnology	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Acumen Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Acumen Pharmaceuticals is trading at a lower price-to-earnings ratio than PDS Biotechnology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PDS Biotechnology	N/A	N/A	-$34.50M	-$0.67	N/A
Acumen Pharmaceuticals	N/A	N/A	-$121.33M	-$1.86	N/A

PDS Biotechnology has a beta of 1.62, meaning that its share price is 62% more volatile than the broader market. Comparatively, Acumen Pharmaceuticals has a beta of 0.36, meaning that its share price is 64% less volatile than the broader market.

Acumen Pharmaceuticals' return on equity of -123.07% beat PDS Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PDS Biotechnology	N/A	-346.02%	-102.36%
Acumen Pharmaceuticals	N/A	-123.07%	-79.41%

26.8% of PDS Biotechnology shares are owned by institutional investors. Comparatively, 71.0% of Acumen Pharmaceuticals shares are owned by institutional investors. 8.4% of PDS Biotechnology shares are owned by company insiders. Comparatively, 10.2% of Acumen Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

Acumen Pharmaceuticals beats PDS Biotechnology on 5 of the 9 factors compared between the two stocks.

Get PDS Biotechnology News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PDSB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PDSB vs. The Competition

Export

Metric	PDS Biotechnology	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$43.36M	$3.72B	$7.06B	$12.95B
Dividend Yield	N/A	3.76%	2.58%	10.20%
P/E Ratio	N/A	9.13	269.75	24.74
Price / Sales	N/A	1,274.20	652.34	108.60
Price / Cash	N/A	44.95	28.89	37.44
Price / Book	4.06	17.66	11.27	6.42
Net Income	-$34.50M	-$13.25M	$3.45B	$347.12M
7 Day Performance	2.34%	5.36%	3.56%	2.48%
1 Month Performance	-5.53%	-1.74%	-0.58%	-1.04%
1 Year Performance	-34.14%	61.36%	77.52%	23.22%

PDS Biotechnology Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PDSB PDS Biotechnology	1.6653 of 5 stars	$0.73 -5.7%	$9.00 +1,131.0%	-30.2%	$43.36M	N/A	N/A	20	Upcoming Earnings Analyst Upgrade
TNYA Tenaya Therapeutics	3.1984 of 5 stars	$0.77 +5.3%	$4.00 +420.8%	+8.7%	$166.66M	N/A	N/A	110	News Coverage Earnings Report Upcoming Earnings Analyst Revision
MOLN Molecular Partners	2.4918 of 5 stars	$4.12 -0.1%	$8.38 +103.5%	+15.4%	$166.16M	$5.65M	N/A	180
IMDX Oncocyte	1.2415 of 5 stars	$5.10 +1.5%	$12.00 +135.2%	N/A	$164.20M	$4.05M	N/A	120	News Coverage Earnings Report
YDES YD Bio	N/A	$2.32 +0.7%	N/A	N/A	$163.88M	$596.82K	N/A	N/A

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PDSB) was last updated on 8/10/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

PDS Biotechnology (PDSB) Competitors

PDSB vs. TNYA, MOLN, IMDX, YDES, and ABOS

How does PDS Biotechnology compare to Tenaya Therapeutics?

Summary

How does PDS Biotechnology compare to Molecular Partners?

Summary

How does PDS Biotechnology compare to Oncocyte?

Summary

How does PDS Biotechnology compare to YD Bio?

Summary

How does PDS Biotechnology compare to Acumen Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PDSB vs. The Competition

PDS Biotechnology Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

PDS Biotechnology (PDSB) Competitors

PDSB vs. TNYA, MOLN, IMDX, YDES, and ABOS

How does PDS Biotechnology compare to Tenaya Therapeutics?

Which has better earnings & valuation, TNYA or PDSB?

Does the media refer more to TNYA or PDSB?

Do institutionals and insiders have more ownership in TNYA or PDSB?

Which has more risk and volatility, TNYA or PDSB?

Is TNYA or PDSB more profitable?

Do analysts rate TNYA or PDSB?

Summary

How does PDS Biotechnology compare to Molecular Partners?

Do analysts rate MOLN or PDSB?

Which has more volatility and risk, MOLN or PDSB?

Is MOLN or PDSB more profitable?

Do insiders and institutionals have more ownership in MOLN or PDSB?

Which has higher earnings and valuation, MOLN or PDSB?

Does the media refer more to MOLN or PDSB?

Summary

How does PDS Biotechnology compare to Oncocyte?

Do analysts rate PDSB or IMDX?

Which has more risk & volatility, PDSB or IMDX?

Is PDSB or IMDX more profitable?

Do insiders & institutionals hold more shares of PDSB or IMDX?

Which has preferable valuation and earnings, PDSB or IMDX?

Does the media refer more to PDSB or IMDX?

Summary

How does PDS Biotechnology compare to YD Bio?

Does the media favor YDES or PDSB?

Is YDES or PDSB more profitable?

Do analysts prefer YDES or PDSB?

Do insiders and institutionals believe in YDES or PDSB?

Which has stronger earnings & valuation, YDES or PDSB?

Summary

How does PDS Biotechnology compare to Acumen Pharmaceuticals?

Do analysts prefer PDSB or ABOS?

Does the media refer more to PDSB or ABOS?

Which has better valuation & earnings, PDSB or ABOS?

Which has more risk and volatility, PDSB or ABOS?

Is PDSB or ABOS more profitable?

Do insiders & institutionals believe in PDSB or ABOS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PDSB vs. The Competition

PDS Biotechnology Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools